C. Guico-Pabia

发表

Effect of Desvenlafaxine on the Cytochrome P450 2D6 Enzyme System

S. Preskorn, J. Paul, A. Nichols, 2008, Journal of psychiatric practice.

Improving quality of depression care using organized systems of care: a review of the literature.

W. Katon, C. Guico-Pabia, 2011, The Primary Care Companion For CNS Disorders.

Cardiovascular, cerebrovascular, and hepatic safety of desvenlafaxine for 1 year in women with vasomotor symptoms associated with menopause

D. Archer, J. Pinkerton, C. Guico-Pabia, 2012, Menopause.

Indirect cost of ischemic heart disease to employers.

S. Teutsch, J. Murray, A. Wertheimer, 2001, The American journal of managed care.

Maintenance of the efficacy of desvenlafaxine in menopausal vasomotor symptoms: a 1-year randomized controlled trial

D. Archer, J. Pinkerton, C. Guico-Pabia, 2012, Menopause.

An Assessment of Drug-Drug Interactions: The Effect of Desvenlafaxine and Duloxetine on the Pharmacokinetics of the CYP2D6 Probe Desipramine in Healthy Subjects

J. Paul, M. Burczynski, A. Nichols, 2008, Drug Metabolism And Disposition.

Venlafaxine Metabolism as a Marker of Cytochrome P450 Enzyme 2D6 Metabolizer Status

S. Preskorn, J. Paul, A. Nichols, 2009, Journal of clinical psychopharmacology.

A Meta-analysis of Factors Impacting Detection of Antidepressant Efficacy in Clinical Trials: The Importance of Academic Sites

M. Thase, B. Dunlop, P. Ninan, 2012, Neuropsychopharmacology.

Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.

S. Kornstein, C. Guico-Pabia, S. Reddy, 2010, The Journal of clinical psychiatry.

Beyond symptomatic improvement:assessing real-world outcomes in patients with major depressive disorder.

A. Langlieb, C. Guico-Pabia, 2010, Primary care companion to the Journal of clinical psychiatry.

Classification : Statistical : 1-3 Strategic : 4-17 Clinical : 18-23 1 Statistical Considerations for the Analysis of Suicidal Ideation and Behavior Events in Clinical Trials

M. Thase, B. Dunlop, P. Ninan, 2022 .

Abstracts from the 7th international forum on mood and anxiety disorders

C. Guico-Pabia, P. Fatato, S. Connolly, 2007, International journal of psychiatry in clinical practice.

Recognition of depression among women presenting with menopausal symptoms

A. Clayton, C. Guico-Pabia, 2008, Menopause.

Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician

P. Ninan, B. Pitrosky, C. Guico-Pabia, 2010, Current medical research and opinion.

Menstrual cycle-related exacerbation of disease.

H. Taylor, J. Pinkerton, C. Guico-Pabia, 2010, American journal of obstetrics and gynecology.

Antidepressant Treatment and Altered CYP2D6 Activity: Are Pharmacokinetic Variations Clinically Relevant?

S. Preskorn, C. Guico-Pabia, Inna D’Empaire, 2011, Journal of psychiatric practice.

Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.

S. Preskorn, R. Fayyad, A. Nichols, 2013, The Journal of clinical psychiatry.

The effect of desvenlafaxine on cognitive functioning in employed outpatients with major depressive disorder: a substudy of a randomized, double-blind, placebo-controlled trial

K. Wesnes, R. Fayyad, C. Guico-Pabia, 2016, Journal of psychopharmacology.

Effects of desvenlafaxine on blood pressure in patients treated for major depressive disorder: a pooled analysis

M. Thase, J. Sporn, R. Fayyad, 2015, Current medical research and opinion.

Assessing the relationship between functional impairment/recovery and depression severity: a pooled analysis

C. Soares, R. Fayyad, C. Guico-Pabia, 2012, International clinical psychopharmacology.

Post hoc analysis of the efficacy and safety of desvenlafaxine 50 mg/day in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder

S. Kornstein, A. Clayton, W. Bao, 2014, Menopause.

Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder

M. Thase, P. Ninan, S. Kornstein, 2010, Menopause.

Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder.

S. Preskorn, P. Ninan, J. Paul, 2010, The Journal of clinical psychiatry.

Efficacy of the selective extrasynaptic GABA A agonist, gaboxadol, in a model of transient insomnia: a randomized, controlled clinical trial.

D. Mayleben, S. Deacon, C. Guico-Pabia, 2008, Sleep medicine.

A Post Hoc Analysis of the Effect of Weight on Efficacy in Depressed Patients Treated With Desvenlafaxine 50 mg/d and 100 mg/d.

R. McIntyre, R. Fayyad, M. Boucher, 2015, The primary care companion for CNS disorders.

Predictors of functional improvement in employed adults with major depressive disorder treated with desvenlafaxine

J. Endicott, R. Lam, M. Hsu, 2014, International clinical psychopharmacology.

Predictors of functional response and remission with desvenlafaxine 50 mg/d in patients with major depressive disorder

J. Endicott, C. Soares, R. Fayyad, 2014, CNS Spectrums.

Early Improvement in Depressive Symptoms With Desvenlafaxine 50 mg/d as a Predictor of Treatment Success in Patients With Major Depressive Disorder

C. Soares, R. Fayyad, C. Guico-Pabia, 2014, Journal of clinical psychopharmacology.

An Integrated Analysis of the Efficacy of Desvenlafaxine Compared with Placebo in Patients with Major Depressive Disorder

M. Thase, P. Ninan, S. Kornstein, 2009, CNS Spectrums.

BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine

R. Shelton, P. Ninan, W. Bao, 2014, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Symptomatic and Functional Improvement in Employed Depressed Patients: A Double-Blind Clinical Trial of Desvenlafaxine Versus Placebo

B. Dunlop, S. Lubaczewski, C. Guico-Pabia, 2011, Journal of clinical psychopharmacology.

An Integrated Analysis of the Safety and Tolerability of Desvenlafaxine Compared with Placebo in the Treatment of Major Depressive Disorder

S. Kornstein, A. Clayton, C. Guico-Pabia, 2009, CNS Spectrums.

Incidence and Timing of Taper/Posttherapy-Emergent Adverse Events Following Discontinuation of Desvenlafaxine 50 mg/d in Patients With Major Depressive Disorder.

P. Ninan, T. Ramey, M. Messig, 2015, The primary care companion for CNS disorders.

Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials.

M. Thase, S. Kornstein, C. Soares, 2009, The Journal of clinical psychiatry.

Analysis by Age and Sex of Efficacy Data From Placebo-Controlled Trials of Desvenlafaxine in Outpatients With Major Depressive Disorder

S. Kornstein, C. Soares, S. K. Padmanabhan, 2010, Journal of clinical psychopharmacology.

A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women.

S. Kornstein, A. Clayton, W. Bao, 2015, Journal of women's health.

Real-World Disparities Between Patient- and Clinician-Reported Outcomes: Results From a Disease-Specific Program in Depression and Anxiety

R. Fayyad, S. Lubaczewski, C. Guico-Pabia, 2014, Professional case management.

The Lucent-Takes-Heart Cardiovascular Health Management Program

C. Guico-Pabia, L. G. Shoner, L. Cioffi, 2002, AAOHN journal : official journal of the American Association of Occupational Health Nurses.

Efficacy of desvenlafaxine 50 mg compared with placebo in patients with moderate or severe major depressive disorder: a pooled analysis of six randomized, double-blind, placebo-controlled studies

G. Papakostas, L. Culpepper, R. Fayyad, 2013, International clinical psychopharmacology.

Open-Label Treatment with Desvenlafaxine in Postmenopausal Women with Major Depressive Disorder Not Responding to Acute Treatment with Desvenlafaxine or Escitalopram

M. Thase, S. Kornstein, C. Soares, 2011, CNS Drugs.

Real-World Disparities Between Patient- and Clinician-Reported Outcomes: Results From a Disease-Specific Program in Depression and Anxiety

R. Fayyad, S. Lubaczewski, C. Guico-Pabia, 2014, Professional case management.

Symptomatic and Functional Improvement in Employed Depressed Patients: A Double-Blind Clinical Trial of Desvenlafaxine Versus Placebo

B. Dunlop, S. Lubaczewski, C. Guico-Pabia, 2011, Journal of clinical psychopharmacology.

BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine

R. Shelton, P. Ninan, W. Bao, 2014, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Improvements in quality of life with desvenlafaxine 50mg/d vs placebo in employed adults with major depressive disorder.

J. Endicott, R. Lam, M. Hsu, 2014, Journal of affective disorders.

The effect of desvenlafaxine 50 mg/day on a subpopulation of anxious/depressed patients: a pooled analysis of seven randomized, placebo‐controlled studies

S. Kornstein, R. Fayyad, C. Guico-Pabia, 2014, Human psychopharmacology.

Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician

P. Ninan, B. Pitrosky, C. Guico-Pabia, 2010, Current medical research and opinion.